Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2,3-dihydro-n-2-propynyl-1h-inden-1-amine-(1r)-hydrochloride
2. Agn 1135
3. Agn-1135
4. Azilect
5. N-2-propynyl-1-indanamine
6. N-propargyl-1-aminoindan Mesylate
7. Rasagiline
8. Rasagiline Hydrochloride
9. Tvp 101
10. Tvp 1022
11. Tvp-101
12. Tvp-1022
13. Tvp1022
1. 161735-79-1
2. Azilect
3. Rasagiline Mesilate
4. Tvp-1012
5. Agilect
6. (r)-n-(prop-2-yn-1-yl)-2,3-dihydro-1h-inden-1-amine Methanesulfonate
7. Rasagiline Methanesulfonate
8. Rasagiline Mesylate [usan]
9. Rasagiline (mesylate)
10. Rasagline Ratiopharm
11. Rasagiline (as Mesilate)
12. Lh8c2ji290
13. (r)-n-2-propynyl-1-indanamine Methanesulfonate
14. 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (r)-, Methanesulfonate
15. Methanesulfonic Acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine
16. Ncgc00168774-01
17. Azilect (tn)
18. Mfcd08460604
19. 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, Methanesulfonate
20. Rasagiline Mesilate (jan)
21. Rasagiline Mesylate (usan)
22. Dsstox_cid_27826
23. Dsstox_rid_82589
24. Dsstox_gsid_47848
25. Rasagiline Mesilate [jan]
26. Tvp1012
27. Cas-161735-79-1
28. Tvp 1012
29. Unii-lh8c2ji290
30. C12h13n.ch3so3h
31. Schembl158439
32. (1r)-2,3-dihydro-n-2-propynyl-1h-inden-1-amine Methanesulfonate
33. (r)-2,3-dihydro-n-2-propynyl-1-indenamine Mesylate
34. Chembl1201142
35. Dtxsid8047848
36. Hms3884d07
37. Rasagiline Mesylate [vandf]
38. (1r)-2,3-dihydro-n-2-propyn-1-yl-1h-inden-1-amine Mesylate
39. Act06733
40. Rasagiline Mesilate [mart.]
41. Tox21_112635
42. Ac-724
43. Rasagiline Mesylate [who-dd]
44. S2102
45. Akos005145768
46. Rasagiline Mesylate, >=98% (hplc)
47. Tox21_112635_1
48. Bs-1009
49. Ccg-267122
50. Tv 1012
51. 1h-inden-1-amine, 2,3-dihydro-n-2-propyn-1-yl-, (1r)-, Methanesulfonate (1:1)
52. Rasagiline Methanesulfonate [mi]
53. Ncgc00168774-02
54. Rasagiline Mesylate [orange Book]
55. (+)-agn-1135
56. Hy-14605
57. R0213
58. D02562
59. 735r791
60. Q-101873
61. Q27282989
62. (r)-n-2-propynyl-1-indanamine Methanesulphonate
63. Z1820079046
64. (1r)-2,3-dihydro-n-2-propynyl-1h-in Den-1-amine Methanesulfonate
65. (r)-n-(prop-2-ynyl)-2,3-dihydro-1h-inden-1-amine Methanesulfonate
66. (1r)-n-(prop-2-yn-1-yl)-2,3-dihydro-1h-inden-1-amine; Methanesulfonic Acid
67. 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (r)-, Methanesulphonate
Molecular Weight | 267.35 g/mol |
---|---|
Molecular Formula | C13H17NO3S |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 2 |
Exact Mass | 267.09291458 g/mol |
Monoisotopic Mass | 267.09291458 g/mol |
Topological Polar Surface Area | 74.8 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 305 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Azilect |
Drug Label | AZILECT tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinsons disease. It is designated chemically as: 1H-Inden-1-amine, 2, 3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate... |
Active Ingredient | Rasagiline mesylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 0.5mg base; eq 1mg base |
Market Status | Prescription |
Company | Teva |
2 of 4 | |
---|---|
Drug Name | Rasagiline mesylate |
PubMed Health | Rasagiline (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | AZILECT tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinsons disease. It is designated chemically as: 1H-Inden-1-amine, 2, 3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate... |
Active Ingredient | Rasagiline mesylate |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | eq 0.5mg base; 0.5mg; 1mg; eq 1mg base |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharma; Apotex |
3 of 4 | |
---|---|
Drug Name | Azilect |
Drug Label | AZILECT tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinsons disease. It is designated chemically as: 1H-Inden-1-amine, 2, 3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate... |
Active Ingredient | Rasagiline mesylate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 0.5mg base; eq 1mg base |
Market Status | Prescription |
Company | Teva |
4 of 4 | |
---|---|
Drug Name | Rasagiline mesylate |
PubMed Health | Rasagiline (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | AZILECT tablets contain rasagiline (as the mesylate), a propargylamine-based drug indicated for the treatment of idiopathic Parkinsons disease. It is designated chemically as: 1H-Inden-1-amine, 2, 3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate... |
Active Ingredient | Rasagiline mesylate |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | eq 0.5mg base; 0.5mg; 1mg; eq 1mg base |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharma; Apotex |
Azilect is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.
Monoamine Oxidase Inhibitors
A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)
Neuroprotective Agents
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)
N04BD02
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm :
NDC Package Code : 55111-900
Start Marketing Date : 2010-01-18
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17075
Submission : 2004-01-07
Status : Inactive
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-08-20
Pay. Date : 2016-06-16
DMF Number : 30600
Submission : 2016-06-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22782
Submission : 2009-05-15
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-06-28
Pay. Date : 2016-06-08
DMF Number : 22366
Submission : 2008-12-30
Status : Active
Type : II
Date of Issue : 2019-10-11
Valid Till : 2022-07-02
Written Confirmation Number : WC-0157
Address of the Firm :
NDC Package Code : 65015-775
Start Marketing Date : 2015-02-19
End Marketing Date : 2026-12-01
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2019-04-10
Registration Number : Su289-6-ND
Manufacturer Name : Viyash Life Sciences Private Limited
Manufacturer Address : Plot No.1-A/2 & Plot No. 1-A/3, MIDC Taloja Industrial Area, Taloja - 410208 Taluka: Panvel, District RAIGAD. Maharashtra, India
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-09-06
Pay. Date : 2013-02-21
DMF Number : 24159
Submission : 2010-09-01
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-03
Pay. Date : 2012-12-20
DMF Number : 26599
Submission : 2012-12-21
Status : Active
Type : II
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0057n
Address of the Firm :
NDC Package Code : 66039-878
Start Marketing Date : 2013-05-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Chong Kun Dang Co., Ltd.
Registration Date : 2020-07-15
Registration Number : Su434-9-ND(4)
Manufacturer Name : Glenmark Life Sciences Limited.
Manufacturer Address : Plot No 3109, GIDC Industrial Estate, Ankleshwar - 393 002, Dist. Bharuch, Gujarat State, India
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23687
Submission : 2010-05-07
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm : Chemical Technical Operations Unit-VI, APIIC Industrial Estate, Pydibhimavaram V...
Date of Issue : 2022-07-23
Valid Till : 2025-09-05
Written Confirmation Number : WC-0370n
Address of the Firm : Survey No.- 85 to 88, N.H. No.-8, Naugama, At & Post-Mandva, Tal. - Ankleshwar, ...
Date of Issue : 2020-11-27
Valid Till : 2021-06-07
Written Confirmation Number : WC-0317A2
Address of the Firm : Plot.No 43 & 44, IDA Phase-II, Pashamylaram, Patancheru Mandal, Medak Disctrict,...
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0057n
Address of the Firm : Plot No. 3109, GIDC, Industrial Estate, Ankleshwar-393 002, Bharuch, Gujarat
Date of Issue : 2019-07-15
Valid Till : 2022-07-15
Written Confirmation Number : WC-0152
Address of the Firm : (Kilo Lab), R-92-93, 1st Floor, TTC MIDC Thane Belapur Road, Rabale, Navi Mumbai...
Date of Issue : 2019-11-28
Valid Till : 2022-07-02
Written Confirmation Number : WC-0079
Address of the Firm : Plot No.2209, GIDC, Industrial Estate, At & Post Sarigam, Tal-Umbergaon, Valsad-...
Date of Issue : 2019-08-16
Valid Till : 2022-08-15
Written Confirmation Number : WC-0225
Address of the Firm : 43-45 KIADB Bommasandra Industrial Area, 4th Phase, Anekal Taluk, Bangalore-560 ...
Date of Issue : 2022-05-02
Valid Till : 2025-07-25
Written Confirmation Number : WC-0027
Address of the Firm : Unit-II, Survey No.14, IDA Gaddapotharam (Village), Kazipally, Jinnaram (Mandal)...
Date of Issue : 2022-11-03
Valid Till : 2025-07-02
Written Confirmation Number : WC-0182
Address of the Firm : Sy.no. 239 and 240 Dothigudem Village, Pochampally mandal, Nalgonda, District-50...
Date of Issue : 2019-10-11
Valid Till : 2022-07-02
Written Confirmation Number : WC-0157
Address of the Firm : Plot No. 1A/2, MIDC, Taloja, Panvel, Dist. Raigad, Maharashtra State
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Rasagiline manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rasagiline, including repackagers and relabelers. The FDA regulates Rasagiline manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rasagiline API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rasagiline manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rasagiline supplier is an individual or a company that provides Rasagiline active pharmaceutical ingredient (API) or Rasagiline finished formulations upon request. The Rasagiline suppliers may include Rasagiline API manufacturers, exporters, distributors and traders.
click here to find a list of Rasagiline suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rasagiline DMF (Drug Master File) is a document detailing the whole manufacturing process of Rasagiline active pharmaceutical ingredient (API) in detail. Different forms of Rasagiline DMFs exist exist since differing nations have different regulations, such as Rasagiline USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rasagiline DMF submitted to regulatory agencies in the US is known as a USDMF. Rasagiline USDMF includes data on Rasagiline's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rasagiline USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rasagiline suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Rasagiline Drug Master File in Korea (Rasagiline KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Rasagiline. The MFDS reviews the Rasagiline KDMF as part of the drug registration process and uses the information provided in the Rasagiline KDMF to evaluate the safety and efficacy of the drug.
After submitting a Rasagiline KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Rasagiline API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Rasagiline suppliers with KDMF on PharmaCompass.
A Rasagiline written confirmation (Rasagiline WC) is an official document issued by a regulatory agency to a Rasagiline manufacturer, verifying that the manufacturing facility of a Rasagiline active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Rasagiline APIs or Rasagiline finished pharmaceutical products to another nation, regulatory agencies frequently require a Rasagiline WC (written confirmation) as part of the regulatory process.
click here to find a list of Rasagiline suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Rasagiline as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Rasagiline API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Rasagiline as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Rasagiline and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Rasagiline NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Rasagiline suppliers with NDC on PharmaCompass.
Rasagiline Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rasagiline GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rasagiline GMP manufacturer or Rasagiline GMP API supplier for your needs.
A Rasagiline CoA (Certificate of Analysis) is a formal document that attests to Rasagiline's compliance with Rasagiline specifications and serves as a tool for batch-level quality control.
Rasagiline CoA mostly includes findings from lab analyses of a specific batch. For each Rasagiline CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rasagiline may be tested according to a variety of international standards, such as European Pharmacopoeia (Rasagiline EP), Rasagiline JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rasagiline USP).
LOOKING FOR A SUPPLIER?